AAM Opposes HF17 and SF168 Which Won’t Bring Down Drug Prices for Minnesota Patients
Time and time again, lawmakers propose legislation to help reduce drug costs for patients. But all too often, their proposals have the opposite effect: They jeopardize patient access to low-cost medicines. With two newly proposed bills in Minnesota, HF17 SF168, lawmakers have an opportunity to ensure this does not happen in their state. Here’s why […]
Veto Illinois HB 1780 Which Puts Patient Access to Generic Medicines at Risk
The State of Illinois is considering legislation (HB 1780) to establish a statewide drug take back program funded almost exclusively by generic drug manufacturers. HB 1780, as currently drafted, would disproportionately impact the makers of low-cost generic medicines instead of the manufacturers of high-cost brand-name drugs. Generic medicines account for less than 2% of health […]
Kenneth Westberry Joins AAM As Senior Manager, State Government Affairs
WASHINGTON, D.C. (October 27, 2021) — Kenneth Westberry has joined the Association for Accessible Medicines as Senior Manager, State Government Affairs. He will assist AAM’s state government affairs team with strategic, operational and administrative support in pursuit of its advocacy goals and in representing the generics and biosimilars industry across the country. Legislative efforts to […]
AAM Statement on Gov. Mills’ Veto of LD 1117
WASHINGTON DC (June 30, 2021) – AAM applauds Governor Janet Mills (D-ME) for protecting Maine patients’ access to safe, affordable generic medicines by vetoing LD 1117. Governor Mill’s decision to veto this bill on constitutional grounds was the right choice to make. LD 1117 misdiagnosed the problem of high prescription drug costs. Generic medicines save […]
AAM Statement on Governor Mill’s Consideration of LD 1117
WASHINGTON DC (June 18, 2021) – The Maine legislature this week passed a bill, LD 1117, despite warnings that the legislation is unconstitutional. LD 1117, a bill targeting generic prescription medicines, is essentially identical to a Maryland law that was enacted in 2017. To ensure access to generic medicines for patients nationwide, the Association for […]
AAM Statement on Maine LD 1117
WASHINGTON DC (June 16, 2021) – “The Association for Accessible Medicines (AAM) strongly encourages the Maine House of Representatives to oppose LD 1117. The fact is generic medicines drive cost savings for patients and increase access to life-saving treatments. According to the Maine Health Data Organization, every one of the 25 most costly prescription drugs […]
SB 764 Will Hurt Oregon’s Most Vulnerable Patients
WASHINGTON, D.C. (April 22, 2021) — The Association for Accessible Medicines (AAM), representing manufacturers of reliable, low-cost generic drugs, is disappointed that the Oregon State Senate voted to pass a measure that will increase the cost of prescription drugs for Oregonians. Patent settlements have taken years off the monopoly protections that some of the most […]
Oppose Oregon SB 764
AAM Opposes Legislation That Conflicts with Federal Law and Delays Patient Access to More Affordable Medicine Oregon SB 764 Would Delay Patient Access to Lower-Cost Generic and Biosimilar Medicines Patent settlements expedite access to lower-cost life-saving generic and biosimilar medicines for patients and ensure continued investment to bring these affordable medicines to market. A study […]
Health Care Savings, State by State
Generic prescription medicines save patients more money with each passing year. In 2019, according to AAM’s Generic Drug & Biosimilars Access & Savings in the U.S. Report (with data provided by IQVIA), savings from generic drugs added up to $313 billion. The 50 states saved on average $6.1 billion savings in 2019, including $1.9 billion […]
Amend Connecticut House Bill 5384
Don’t Harm Patient Access to FDA-Approved Generic Medicines by Chilling Generic Drug Competition Everyone supports containing skyrocketing prescription drug prices but Connecticut H.B. 5384 will actually just make the problem worse for Connecticut patients and our economy. Generic medicines saved Connecticuters $2.9 billion in the year 2016 alone. While well-intentioned, this bill doesn’t address the […]
Oppose Louisiana House Bill 243
Don’t Harm Patient Access To FDA-Approved Generic Medicines By Chilling Generic Drug Competition Everyone supports containing skyrocketing prescription drug prices, but H.B. 243 is misguided and would actually make the problem worse for Louisiana patients and our economy. The same bill became law in Maryland but was later found unconstitutional. While well-intentioned, H.B. 243 doesn’t […]
Oppose Maryland House Bill 1194 & Senate Bill 1023
Everyone supports containing skyrocketing prescription drug prices but SB 1023, sponsored by Sen. Joan Carter Conway (D-Baltimore City), and HB 1194, sponsored by Del. Joseline Pena-Melnyk (D-Anne Arundel & Prince George’s Counties), would actually just make the problem worse for Maryland patients and our economy. Generic medicines represent 89 percent of prescriptions filled in the […]
